心瑋醫療-B(06609.HK):SUPSELEK微導管獲FDA授予許可
格隆匯2月24日丨心瑋醫療-B(06609.HK)宣佈,美利堅合眾國食品藥品監督管理局("FDA")最近根據《食品、藥品及化粧品法案》(Food, Drugand Cosmetic Act)對公司的SupSelek™微導管授予510k許可。
截至公吿日期,公司已取得FDA對SupSelek™微導管及Fullblock™封堵球囊導管兩款產品授予510k許可。公司將繼續於海外為其產品申請許可及註冊。
公司無法保證最終將能成功把SupSelek™微導管或Fullblock™封堵球囊導管市場推廣及╱或商業化。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.